| Code | CSB-RA859530MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to visugromab, targeting growth differentiation factor 15 (GDF15), a stress-responsive cytokine member of the TGF-β superfamily. GDF15 is minimally expressed under normal physiological conditions but becomes significantly upregulated in response to cellular stress, tissue injury, inflammation, and various pathological states. Elevated GDF15 levels are associated with cancer progression, cardiovascular disease, metabolic disorders, and cachexia, where it plays a key role in appetite regulation, energy metabolism, and inflammatory responses. The protein signals through its receptor GFRAL in the brainstem, influencing metabolic homeostasis and body weight regulation.
Visugromab is a clinical-stage therapeutic antibody designed to neutralize GDF15, initially developed for treating cancer-associated cachexia and anorexia. This biosimilar provides researchers with a valuable tool for investigating GDF15-mediated pathways in disease models, exploring metabolic regulation mechanisms, and studying potential therapeutic interventions in conditions characterized by aberrant GDF15 expression. It supports diverse research applications in oncology, metabolism, and inflammatory disease studies.
There are currently no reviews for this product.